07.02.23
Deerfield, IL
www.no7company.com
Sales: $862 Million
Key Personnel: Rosalind Brewer, CEO, Walgreens Boots Alliance; Ornella Barra, COO, international, Walgreens Boots Alliance, Inc.; James Kehoe, EVP/global CFO, Walgreens Boots Alliance, Inc.; Danielle Gray, EVP/global chief legal officer, Walgreens Boots Alliance, Inc.; Holly May, EVP/global chief human resources officer, Walgreens Boots Alliance, Inc.; Anita Allemand, chief transformation and integration officer, Walgreens Boots Alliance, Inc.; John Standley, EVP, Walgreens Boots Alliance, Inc. and president, Walgreens; Sebastian James, SVP and managing director, Boots; Annie Murphy, SVP, global chief commercial brands officer and international retail; Aaron Radelet, SVP, global chief communications officer; Charles V. Greener, SVP, global chief public affairs officer; Carlos Cubia, SVP/global chief diversity officer; Francesco Tinto, SVP/global chief information officer; Dr. Mike Bell, head of science research at Walgreens Boots Alliance; Anisha Raghavan, NA CEO, No7
Major Products: Cosmetics, skin care and personal care. Brands include No7, Liz Earle Beauty, Soap & Glory, Botanics, Sleek Makeup
New Products: No7 Future Renew skin care, Soap & Glory Peach Please cleansers
Comments: During the American Academy of Dermatology annual meeting earlier this year, No7 highlighted its new matrix-derived peptide blend, dubbed “Matrikine.” It was the first time No7 exhibited at AAD.
The technology is in new No7 Future Renew; a collection of four skincare products that are said to reverse the appearance of multiple signs of skin damage. The new super peptide is said to be both highly potent and highly tolerated, being suitable even for those with sensitive skin. The No7 Future Renew range has undergone the most extensive and diverse testing program in No7’s history—37 studies on over 4,200 people, including two clinical trials and 23 user trials. More than half (51%) of the total testing group had skin of color.
“Skin damage happens throughout our lives and is caused by multiple factors including sun exposure, environmental pollution, stress, sleep, temperature and nutrition,” said No7’s Head of Science Research Dr. Mike Bell.
The peptide “tricks” skin into thinking that it has been damaged leading to renewal of key proteins such as collagen and fibrillin. It supports skin’s natural self-repair mechanisms, targeting signs of cumulative damage, according to company executives.
www.no7company.com
Sales: $862 Million
Key Personnel: Rosalind Brewer, CEO, Walgreens Boots Alliance; Ornella Barra, COO, international, Walgreens Boots Alliance, Inc.; James Kehoe, EVP/global CFO, Walgreens Boots Alliance, Inc.; Danielle Gray, EVP/global chief legal officer, Walgreens Boots Alliance, Inc.; Holly May, EVP/global chief human resources officer, Walgreens Boots Alliance, Inc.; Anita Allemand, chief transformation and integration officer, Walgreens Boots Alliance, Inc.; John Standley, EVP, Walgreens Boots Alliance, Inc. and president, Walgreens; Sebastian James, SVP and managing director, Boots; Annie Murphy, SVP, global chief commercial brands officer and international retail; Aaron Radelet, SVP, global chief communications officer; Charles V. Greener, SVP, global chief public affairs officer; Carlos Cubia, SVP/global chief diversity officer; Francesco Tinto, SVP/global chief information officer; Dr. Mike Bell, head of science research at Walgreens Boots Alliance; Anisha Raghavan, NA CEO, No7
Major Products: Cosmetics, skin care and personal care. Brands include No7, Liz Earle Beauty, Soap & Glory, Botanics, Sleek Makeup
New Products: No7 Future Renew skin care, Soap & Glory Peach Please cleansers
Comments: During the American Academy of Dermatology annual meeting earlier this year, No7 highlighted its new matrix-derived peptide blend, dubbed “Matrikine.” It was the first time No7 exhibited at AAD.
The technology is in new No7 Future Renew; a collection of four skincare products that are said to reverse the appearance of multiple signs of skin damage. The new super peptide is said to be both highly potent and highly tolerated, being suitable even for those with sensitive skin. The No7 Future Renew range has undergone the most extensive and diverse testing program in No7’s history—37 studies on over 4,200 people, including two clinical trials and 23 user trials. More than half (51%) of the total testing group had skin of color.
“Skin damage happens throughout our lives and is caused by multiple factors including sun exposure, environmental pollution, stress, sleep, temperature and nutrition,” said No7’s Head of Science Research Dr. Mike Bell.
The peptide “tricks” skin into thinking that it has been damaged leading to renewal of key proteins such as collagen and fibrillin. It supports skin’s natural self-repair mechanisms, targeting signs of cumulative damage, according to company executives.